Shareholders Equity: The sum of preferred and common equity items.
4D Molecular Therapeutics, Inc. (FDMT) had Shareholders Equity of $469.72M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.01M |
|
$-47.97M |
|
-- |
|
$0.01M |
|
$53.63M |
|
$-53.62M |
|
$5.65M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-53.62M |
|
$-53.84M |
|
55.74M |
|
55.74M |
|
$-0.86 |
|
$-0.86 |
|
| Balance Sheet Financials | |
$332.57M |
|
$18.75M |
|
$183.16M |
|
$515.73M |
|
$26.90M |
|
-- |
|
$19.11M |
|
$46.01M |
|
$469.72M |
|
$469.72M |
|
|
Shareholders Equity |
$469.72M |
46.33M |
|
| Cash Flow Statement Financials | |
$-47.76M |
|
$31.95M |
|
-- |
|
$149.34M |
|
$133.53M |
|
$-15.81M |
|
$6.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.36 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-383007.20% |
|
-383007.20% |
|
-- |
|
-342657.10% |
|
-342657.10% |
|
$-48.39M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-10.21% |
|
-10.21% |
|
-9.30% |
|
-10.21% |
|
$10.14 |
|
$-0.87 |
|
$-0.86 |
|